IOVA - ライオン・バイオテクノロジ―ズ (Iovance Biotherapeutics Inc.) ライオン・バイオテクノロジ―ズ

 IOVAのチャート


 IOVAの企業情報

symbol IOVA
会社名 Iovance Biotherapeutics Inc (ライオン・バイオテクノロジ―ズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アイオワンス・バイオセラピューティクス(Iovance Biotherapeutics Inc.)(旧名:Lion Biotechnologies Inc)は臨床段階バイオ医薬品会社である。同社は患者自身の免疫システムによって癌細胞を根絶する癌免疫療法製品の開発・商業化に従事する。同社ののリードプログラムは転移性メラノーマの治療のために患者の腫瘍に由来するT細胞である腫瘍浸潤リンパ球を利用する養子細胞療法である。同社は子宮頸癌および頭頸部癌を治療するためにLN-145を開発中である。同社は眼科用メラノーマ、膀胱癌、乳癌、肺癌などの他の固形腫瘍適応症における非改変TILを評価するために国立癌研究所と共同研究を行う。同社はチェックポイントインヒビターKeytrudaと組み合わせてTILを評価するためにNCIと協力する。  ライオン・バイオテクノロジ―ズは米国のバイオ医薬品会社。転移性黒色腫、およびその他固形腫瘍に焦点を充てた新薬の開発に注力する。転移性黒色腫、およびその他固形腫瘍治療向けに、自家腫瘍浸潤リンパ球を使用した養子免疫療法の開発と商品化を手掛ける。本社はカリフォルニア州。   Iovance Biotherapeutics aims to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers. Tumor infiltrating lymphocyte (TIL) therapy uses a patient's own immune cells to attack cancer. TIL cells are extracted from a patient's own tumor tissue, expanded through a proprietary process, and infused back into the patient. Upon infusion, TIL reach tumor tissue, where they attack cancer cells. The company has completed dosing in pivotal programs in patients with metastatic melanoma and cervical cancer. In addition, the company's TIL therapy is being investigated in a registration-supporting study for the treatment of patients with locally advanced, recurrent or metastatic non-small cell lung cancer. Clinical studies are also underway to evaluate TIL in earlier stage cancers in combination with currently approved treatments, and to investigate Iovance peripheral blood lymphocyte (PBL) T cell therapy for blood cancers.
本社所在地 999 Skyway Road Suite 150 San Carlos CA 94070 USA
代表者氏名 Iain D. Dukes イアン・D・デュークス
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 650-260-7120
設立年月日 39326
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 63人
url www.lionbio.com
nasdaq_url https://www.nasdaq.com/symbol/iova
adr_tso
EBITDA EBITDA(百万ドル) -105.72800
終値(lastsale) 10.92
時価総額(marketcap) 1043866485.48
時価総額 時価総額(百万ドル) 1134.795
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 858.70200
当期純利益 当期純利益(百万ドル) -105.17800
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Iovance Biotherapeutics Inc revenues was not reported. Net loss increased 30% to $57.2M. Higher net loss reflects Research and development - Balancing val increase of 21% to $40.1M (expense) General_Administrative - Balancing val increase of 81% to $8.8M (expense) Stock-based Compensation in SGA increase of 50% to $4.9M (expense).

 IOVAのテクニカル分析


 IOVAのニュース

   NASDSQ:IOVA Shareholder Alert: Investigation Concerning Possible Wrongdoing at Iovance Biotherapeutics, Inc.  2021/07/01 16:15:00 SBWire
An investigation on behalf of investors in Iovance Biotherapeutics, Inc. (NASDSQ:IOVA) shares over potential wrongdoing at Iovance Biotherapeutics, Inc. was announced. San Diego, CA -- ( SBWIRE ) -- 07/01/2021 -- Certain directors of Iovance Biotherapeutics, Inc. are under investigation over potential breaches of fiduciary duties. Investors who purchased shares of Iovance Biotherapeutics, Inc. (NASDSQ: IOVA) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain Iovance Biotherapeutics directors breached their fiduciary duties and caused damage to the company and its shareholders. San Carlos, CA based Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient''s immune system to eradicate cancer cells. Iovance Biotherapeutics, Inc. reported that its Net Loss increased from $197.55 million in 2019 to $259.58 million in 2020.
   Iovance Biotherapeutics to Host Conference Call and Webcast to Discuss Clinical Data for LN-145 in Non-Small Cell Lung Cancer on June 29, 2021 at 4:30pm ET  2021/06/29 19:38:00 Intrado Digital Media
SAN CARLOS, Calif., June 29, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, announced that Management will host a conference call and live audio webcast to discuss the recent clinical data for LN-145 TIL therapy in non-small cell lung cancer today at 4:30 p.m. ET.
   Iovance Biotherapeutics Announces Clinical Data for LN-145 in Non-Small Cell Lung Cancer - Stocks News Feed  2021/06/29 10:30:00 Stocks News Feed
21.4% Overall Response Rate (ORR) in Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer (mNSCLC) Patients Following One or More Prior Systemic Therapies Including Immunotherapy First Patient Dosed in Registration-Supporting IOV-LUN-202 Study in Second Line mNSCLC SAN CARLOS, Calif., June 29, 2021 (GLOBE NEWSWIRE) Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based Read More »Iovance Biotherapeutics Announces Clinical Data for LN-145 in Non-Small Cell Lung Cancer
   Is Iovance Biotherapeutics, Inc. (IOVA) A Good Stock To Buy?  2021/06/28 19:19:16 Insider Monkey
   Iovance Bio reports 33-month follow up data for lifileucel in advanced melanoma at ASCO21  2021/06/07 04:35:28 Seeking Alpha
   NASDSQ:IOVA Shareholder Alert: Investigation Concerning Possible Wrongdoing at Iovance Biotherapeutics, Inc.  2021/07/01 16:15:00 SBWire
An investigation on behalf of investors in Iovance Biotherapeutics, Inc. (NASDSQ:IOVA) shares over potential wrongdoing at Iovance Biotherapeutics, Inc. was announced. San Diego, CA -- ( SBWIRE ) -- 07/01/2021 -- Certain directors of Iovance Biotherapeutics, Inc. are under investigation over potential breaches of fiduciary duties. Investors who purchased shares of Iovance Biotherapeutics, Inc. (NASDSQ: IOVA) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain Iovance Biotherapeutics directors breached their fiduciary duties and caused damage to the company and its shareholders. San Carlos, CA based Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient''s immune system to eradicate cancer cells. Iovance Biotherapeutics, Inc. reported that its Net Loss increased from $197.55 million in 2019 to $259.58 million in 2020.
   Iovance Biotherapeutics to Host Conference Call and Webcast to Discuss Clinical Data for LN-145 in Non-Small Cell Lung Cancer on June 29, 2021 at 4:30pm ET  2021/06/29 19:38:00 Intrado Digital Media
SAN CARLOS, Calif., June 29, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, announced that Management will host a conference call and live audio webcast to discuss the recent clinical data for LN-145 TIL therapy in non-small cell lung cancer today at 4:30 p.m. ET.
   Iovance Biotherapeutics Announces Clinical Data for LN-145 in Non-Small Cell Lung Cancer - Stocks News Feed  2021/06/29 10:30:00 Stocks News Feed
21.4% Overall Response Rate (ORR) in Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer (mNSCLC) Patients Following One or More Prior Systemic Therapies Including Immunotherapy First Patient Dosed in Registration-Supporting IOV-LUN-202 Study in Second Line mNSCLC SAN CARLOS, Calif., June 29, 2021 (GLOBE NEWSWIRE) Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based Read More »Iovance Biotherapeutics Announces Clinical Data for LN-145 in Non-Small Cell Lung Cancer
   Is Iovance Biotherapeutics, Inc. (IOVA) A Good Stock To Buy?  2021/06/28 19:19:16 Insider Monkey
   Iovance Bio reports 33-month follow up data for lifileucel in advanced melanoma at ASCO21  2021/06/07 04:35:28 Seeking Alpha
   Iovance Bio reports 33-month follow up data for lifileucel in advanced melanoma at ASCO21  2021/06/07 04:35:28 Seeking Alpha
   Iovance Biotherapeutics posts positive data from lifileucel combo cancer trial  2021/06/04 13:20:46 Seeking Alpha
   Iovance: Down And Rebound  2021/05/30 13:34:00 Seeking Alpha

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ライオン・バイオテクノロジ―ズ IOVA Iovance Biotherapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)